Smith+Nephew signs exclusive US distribution agreement with RMR Ortho for patented technology that provides a unique dynamic compression nitinol fixation option (A'TOMIC) to our surgeons
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has signed an exclusive US distribution agreement with RMR Ortho to add the A’TOMIC™ Nitinol Fixation System to the Smith+Nephew Trauma, Foot & Ankle and Hand & Wrist portfolio. The system is designed to improve implant integrity and patient comfort
“This partnership with RMR Ortho strengthens Smith+Nephew’s fixation portfolio by adding a dynamic compression fixation solution that complements our existing technologies,” said Scott Gunn, Vice President of U.S. Marketing, Trauma, Extremities, and Shoulder at Smith+Nephew. “The A’TOMIC Nitinol Fixation System expands our ability to participate in high-frequency fracture and arthrodesis procedures while leveraging our established Extremities and Trauma sales channel to deepen surgeon engagement. This collaboration reflects our disciplined approach to portfolio expansion and our continued focus on driving sustainable growth.”
The A’TOMIC™ Nitinol Fixation System leverages proprietary manufacturing methods and the unique properties of nitinol to provide compressive fixation implants featuring a wide bridge with barbed, round legs that match drill holes.
“Partnering with Smith+Nephew represents an important step forward for RMR Ortho as we continue to expand access to the A’TOMIC Nitinol Fixation System across key U.S. territories,” said Joe Ritz, CEO of RMR Ortho. “Smith+Nephew’s established presence in orthopedic extremities and trauma, deep surgeon relationships, and commercial scale make them a strong partner as we work to deliver reliable, continuously compressive fixation solutions to surgeons, hospitals, and patients.”
References
- RMR Ortho. Internal Report Elastic Static Bend Testing of RMR Ortho A’TOMIC Implants.
- RMR Ortho. Internal Report Bending Fatigue Testing of RMR Ortho A’TOMIC Implants.
- RMR Ortho. Internal Report Static Leg Compression Testing of RMR Ortho A’TOMIC Implants.
- RMR Ortho. Internal Report Static Axial Pull-out Testing of RMR Ortho A’TOMIC Implants.
- RMR Ortho. Internal Reports. Simulated Leg Compression Testing of RMR Ortho A’TOMIC Implants.
- Dock CC, Freeman KL, Coetzee JC, McGaver RS, Giveans MR. Outcomes of Nitinol Compression Staples in Tarsometatarsal Fusion. Foot & Ankle Orthopaedics. 2020;5(3). doi:10.1177/2473011420944904
- Duerig T, Pelton A, Stöckel D. An overview of nitinol medical applications, Materials Science and Engineering: A, Volumes 273–275, 1999, Pages 149-160.
- Pelton, Alan R. et al. “Medical Uses of Nitinol.” Materials Science Forum 327-328 (2000): 63 - 70.
- Sleiman A., Bejcek C., Nestler A., Revelt N., Thuppal S., Mills A., Gardner M. The history of orthopaedic use of nitinol compression staples. Injury 2023; 54(11): 111036.
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The script at the end of 2018: The Federal Reserve continued to raise interest rates, US stocks plunged 20% from the September highs, forcing the Federal Reserve to "pivot" in January.
Goldman Sachs' head of trading believes the current US stock market is repeating the scenario of late 2018, with monetary tightening and equity market pressure. The Goldman Sachs Financial Conditions Index has tightened by about 8 points in two weeks, reaching the highest level in a year. The selloff has broadened from tech stocks to defensive sectors. Gold and equities are declining simultaneously, possibly indicating investors are selling assets to raise cash, making gold a key indicator for observing liquidity stress.

Goldman Sachs Trader “Revisits the 2018 Playbook”: Still Clearly Remembers “On December 24th, Clients Asked Why the Market Dropped So Much—And I Had No Idea”
Brian Garrett pointed out that the current adjustment in the US stock market is similar to the sharp decline in Q4 2018: the S&P 500 has already experienced 42% of the corresponding drop, and the VIX is approaching its peak just before Christmas. If history repeats itself, the bottom of this cycle may appear in January next year. However, the credit market and Federal Reserve policy have yet to provide clear signals of a bottom.
Anthropic (ANT.US) nearly “broke issue price,” but Claude knocks on the doors of “the highest peak in mathematics”! 17 million lines of Lean code used to write a candidate proof for the Riemann Hypothesis
On November 20th, Eastern Time, on its second day of trading, Anthropic's intraday price dropped to a low of $83.05, just 5 cents above the offering price of $83, and finally closed at $88.91, a decline of 8.50%. On the same day, the company's mathematician Levant Alperg announced on his personal website that he and Claude had found a candidate proof for the Riemann hypothesis, which has puzzled the mathematics community for 167 years, and released about 17 million lines of Lean formalized code.

As US stocks plummet, the parent company of GTA 6 rises against the market! First-day sales hit a record $3.79 billion; Wall Street shifts focus to next-generation GTA Online.
According to Rentrak data, the global box office of "Grand Theft Auto VI" has also surpassed that of "Avengers: Endgame," the highest-grossing film of all time, which has a global box office of approximately $2.94 billion.

